What is Atara Biotherapeutics, Inc. (ATRA) stock price today?

Atara Biotherapeutics, Inc. (ATRA) is currently trading at $9.48, up 2.71% today.

What is ATRA P/E ratio?

Atara Biotherapeutics, Inc.'s P/E ratio is -7.94. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ATRA return on equity (ROE)?

Atara Biotherapeutics, Inc.'s return on equity (ROE) is 44.67%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Atara Biotherapeutics, Inc.'s market cap?

Atara Biotherapeutics, Inc. has a market capitalization of $85.42M.

NASDAQ · Biotechnology

Atara Biotherapeutics, Inc. (ATRA) Stock

$9.48 +2.71% NASDAQ: ATRA Healthcare

Valuation

Metric	Value
Price	$9.48
Market Cap	$85.42M
P/E Ratio	-7.94
P/B Ratio	-3.81
P/S Ratio	13.63
EPS (TTM)	$0.00
52-Week High	$19.15
52-Week Low	$3.92
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	44.67%
ROA	-79.38%
ROCE	-100.35%
Gross Margin	29.75%
Operating Margin	29.75%
Net Margin	-269.42%
Debt/Equity	-0.27
Current Ratio	0.80

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$20.0M	$64.0M	$9.0M	$129.0M	$121.0M
Operating Profit	$-340.0M	$-281.0M	$-276.0M	$-83.0M	$36.0M
Net Profit	$-340.0M	$-228.0M	$-276.0M	$-85.0M	$33.0M
EPS	$-90.78	$-55.96	$-65.18	$-11.41	$2.57
Op Margin	-1673.8%	-441.3%	-3219.5%	-64.7%	29.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$468.0M	$376.0M	$166.0M	$109.0M	$20.0M
Total Liabilities	$189.0M	$250.0M	$265.0M	$206.0M	$59.0M
Cash	$106.0M	$93.0M	$26.0M	$25.0M	$8.0M
Borrowings	$28.0M	$72.0M	$58.0M	$44.0M	$53.0M

Latest News

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End Investor's Business Daily · Jun 17, 2026 Atara Biotherapeutics Announces Changes to Its Board of Directors Business Wire · Jun 12, 2026 ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know Zacks · May 21, 2026 Atara Biotherapeutics: Q1 Earnings Snapshot Associated Press · May 12, 2026 FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive InvestorsHub · May 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-221.0M	$-270.0M	$-193.0M	$-69.0M	$-51.0M
Investing Cash Flow	$12.0M	$199.0M	$123.0M	$8.0M	$18.0M
Financing Cash Flow	$6.0M	$32.0M	$1.0M	$0	$0
Net Cash Flow	$-94.0M	$-14.0M	$-67.0M	$-1.0M	$-17.0M
Free Cash Flow	$-231.0M	$-275.0M	$-194.0M	$-69.0M	$-51.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.05
EV / EBITDA	-6.67
FCF Yield	-25.93%
Quick Ratio	1.98
Interest Coverage	-5.04
Return 1Y	-7.87%
Return 3Y	-81.33%
Return 5Y	-97.42%

Ownership

Insiders Held16.92%

Institutions Held52.46%

Institutions Float Held63.15%

Institutional Holder	Shares	Report Date
Adage Capital Partners GP L.L.C.	700,000	2026-03-31
Redmile Group, LLC	441,701	2026-03-31
Mackenzie Financial Corporation	313,620	2026-03-31
Vanguard Capital Management LLC	217,862	2026-03-31
Point72 Asset Management, L.P.	194,264	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is led by CEO Anhco Nguyen, employs 153 people, headquartered in US, publicly traded since 2014.

Atara Biotherapeutics, Inc. (ATRA) stock trades at $9.48 with a market capitalization of $85.42M. The stock is valued at a price-to-earnings (P/E) ratio of -7.94, price-to-book of -3.81, price-to-sales of 13.63. Over the past 52 weeks the stock has ranged between $3.92 and $19.15, and currently trades 50.5% below its 52-week high.

On profitability, Atara Biotherapeutics, Inc. generates a return on equity (ROE) of 44.67% — well above the market average, a sign of a high-quality business, return on capital employed of -100.35%, an operating margin of 29.75%, a net profit margin of -269.42%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides